On Thursday, Neuralink, Elon Musk's brain-implant company, announced that it had obtained approval from the U.S. Food and Drug Administration (FDA) to commence its first clinical study involving human participants.

Elon Musk has repeatedly anticipated FDA approval for human trials for his brain-chip company since 2019. However, the company's application was rejected in early 2022, and they have been addressing the FDA's concerns regarding the safety of the experimental implant.

Neuralink expressed its appreciation for the collaborative efforts between their team and the FDA, describing this achievement as a significant initial milestone that will eventually enable their technology to assist numerous individuals. They clarified in a tweet on Thursday that they are not yet accepting participants for a clinical trial.

Neuralink aims to develop a brain implant that can potentially restore mobility to paralyzed individuals and provide remedies for various neurological conditions.

Reuters' request for comment from the U.S. FDA has not received an immediate response.